Integrated needle-free injection and sensing using opto-microfluidics

Projektinformationen

iSENS

ID Finanzhilfevereinbarung: 101158591

DOI

10.3030/101158591

EK-Unterschriftsdatum 11 April 2024

Startdatum 1 Juli 2024

Enddatum 30 Juni 2027

Finanziert unter

• The European Innovation Council (EIC)

Gesamtkosten

€ 2 512 500,00

EU-Beitrag

€ 2 499 999,00

Koordiniert durch

FLOWBEAMS BV
Netherlands

Periodic Reporting for period 1 - iSENS (Integrated needle-free injection and sensing using opto-microfluidics)

Berichtszeitraum: 2024-07-01 bis 2025-06-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Needle-based injections have revolutionised healthcare by providing an efficient delivery method for medications, such as vaccines. However, there are significant drawbacks associated with using needles on a societal, environmental, and technological level. Needle phobia and infection risks can significantly impact patient compliance and safety with medical treatments, while millions of used needles contaminate the environment every day. Lastly, the effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging. With iSENS, we want to revolutionise the experience of people who receive and perform frequent injections. To this end, we are developing and commercialising a portable and needle-free injector called BoldJet. Through the technological breakthrough we present in this project safer, more effective, and minimally invasive injections that do not contaminate our environment. This patient-friendly technology will result in a positive effect on society, allowing millions of people to receive better and more personalised healthcare.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Started different experimental work in our new lab facility. We have hired additional engineers to strengthen the technical team. Together with them we have been working on further development of the jetting and injection technology and related aspects. Furthermore, validation studies have been performed using our prototype device. On a regulatory and business perspective, we have improved our strategy and roadmap towards first market access. Most of the preliminary results are confidential and will be disclosed at a later stage.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

We set up a new office and lab facility for the FlowBeams team to work on the further development of the technology. The development of the injection technology has been speeded up. Collaboration with the University of Twente has led to two scientific manuscripts which are currently in preparation for publication.
From a business perspective, we gained more traction in the cosmetic industry, also emphasized by the CES Innovation Award 2025 in Beauty & Personal Care category.
As the project is still running, most of the preliminary results are confidential and will be disclosed at a later stage.

FlowBeams: Pioneering precise needle-free injection for a healthier world